Kathy D. Miller, MD, and Stephanie L. Graff, MD, discuss sequencing of ADCs for metastatic HER2-low breast cancer including sequencing, toxicities, and clinical trials.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001337. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview

Antibody-Drug Conjugates in Breast Cancer: Current Status and Future Directions https://pubmed.ncbi.nlm.nih.gov/37762027/

Pathological Identification of HER2-Low Breast Cancer: Tips, Tricks, and Troubleshooting for the Optimal Test https://pubmed.ncbi.nlm.nih.gov/37077201/

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35665782/

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE) https://pubmed.ncbi.nlm.nih.gov/32954927/

Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles https://pubmed.ncbi.nlm.nih.gov/38132377/

Subtypes of Breast Cancer https://www.ncbi.nlm.nih.gov/books/NBK583808/

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34404686/

Trastuzumab Deruxtecan in Metastatic Breast Cancer With Variable HER2 Expression: The Phase 2 DAISY Trial https://pubmed.ncbi.nlm.nih.gov/37488289/

Decoding TROP2 in Breast Cancer: Significance, Clinical Implications, and Therapeutic Advancements https://pubmed.ncbi.nlm.nih.gov/37954074/

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd (TRADE DXd) https://clinicaltrials.gov/study/NCT06533826

Drs Kathy Miller and Nancy U. Lin discuss central nervous system involvement in HER2-positive breast cancer, including the biology and management of patients.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001336. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview

Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies https://pubmed.ncbi.nlm.nih.gov/34208287/

Adjuvant Trastuzumab Emtansine in HER2-Positive Breast Cancer Patients With HER2-Negative Residual Invasive Disease in KATHERINE https://pubmed.ncbi.nlm.nih.gov/36117201/

Raising the Bar for Real-World Data in Oncology: Approaches to Quality Across Multiple Dimensions https://pubmed.ncbi.nlm.nih.gov/38241599/

Anti-Angiogenic Therapy: Current Challenges and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/33916438/

ALK-Positive Lung Cancer: A Moving Target https://pubmed.ncbi.nlm.nih.gov/36797503/

Radiotherapy for HER 2 Positive Brain Metastases: Urgent Need for a Paradigm Shift https://pubmed.ncbi.nlm.nih.gov/35326665/

Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Recent Advances and Strategies https://pubmed.ncbi.nlm.nih.gov/38471052/

Stereotactic Radiosurgery and Local Control of Brain Metastases From Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/36433878/

Multi-institutional Validation of Brain Metastasis Velocity, a Recently Defined Predictor of Outcomes Following Stereotactic Radiosurgery https://pubmed.ncbi.nlm.nih.gov/31526671/

Hippocampal Avoidance Whole Brain Radiotherapy in Brain Metastasis Using Volumetric Modulated Arc Therapy: Experience From a Regional Cancer Centre of Eastern India https://pubmed.ncbi.nlm.nih.gov/37795235/

Leptomeningeal Metastases https://emedicine.medscape.com/article/1156338-overview

Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis https://pubmed.ncbi.nlm.nih.gov/35802849/

A Phase I/II Study of Intrathecal Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive (HER2-Positive) Cancer With Leptomeningeal Metastases: Safety, Efficacy, and Cerebrospinal Fluid Pharmacokinetics https://pubmed.ncbi.nlm.nih.gov/35948282/

Tucatinib-Trastuzumab-Capecitabine for Treatment of Leptomeningeal Metastasis in HER2+ Breast Cancer: TBCRC049 Phase 2 Study Results https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.2018

Radiological Response of Leptomeningeal Metastases According to Revised RANO Criteria Is Associated With Overall Survival in Breast Cancer Patients https://pubmed.ncbi.nlm.nih.gov/37243480/

Drs Kathy D. Miller and Heather A. Parsons explore the complexities and evolving strategies in managing HER2+ oligometastatic breast cancer, tackling curative intent, treatment duration, and the promise of emerging biomarkers.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001335. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview

De Novo Oligometastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/37607325/

A Review of Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/30233772/

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108) https://pubmed.ncbi.nlm.nih.gov/34995128/

Stereotactic Body Radiation Therapy for Oligometastatic Breast Cancer: A Retrospective Multicenter Study https://pubmed.ncbi.nlm.nih.gov/34778049/

NRG-BR002: A Phase IIR/III Trial of Standard of Care Systemic Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Resection (SR) for Newly Oligometastatic Breast Cancer (NCT02364557) https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.1007

Systemic Therapies for HER2-Positive Advanced Breast Cancer https://pubmed.ncbi.nlm.nih.gov/38201451/

Oligometastatic Breast Cancer and Metastasis-Directed Treatment: An Aggressive Multimodal Approach to Reach the Cure https://pubmed.ncbi.nlm.nih.gov/36950272/

Circulating Tumor Biomarkers in Early-Stage Breast Cancer: Characteristics, Detection, and Clinical Developments https://pubmed.ncbi.nlm.nih.gov/37941557/

Minimal Residual Disease (MRD) Detection in Solid Tumors Using Circulating Tumor DNA: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/37636270/